[Possibilities and limitations of eye drops for glaucoma therapy].

Ophthalmologe

Glaucoma Service, Wills Eye Hospital, 840 Walnut Street, 19107, Philadelphia, PA, USA.

Published: October 2016

AI Article Synopsis

  • Chronic open-angle glaucoma treatment in Germany primarily involves daily eye drops, with ongoing discussions about the effectiveness and limitations of this approach.
  • The article reviewed literature and clinical experiences, finding that eye drops can reduce intraocular pressure by 15-35% but face challenges in consistent patient use, especially among older populations.
  • Future treatments may include innovative systems for continuous drug release via biodegradable carriers, while current practices need to be customized to each patient, assessing therapy adherence and possibly incorporating surgical options as needed.

Article Abstract

Background: In Germany, chronic open-angle glaucoma is mostly treated by daily eye drop application. The possibilities and limitations of this form of therapy are presented. Reasons for the change in the selection of the preferred substances over time are also discussed and the limits of local drug therapy are described.

Objectives: What effects can be expected of the available drugs?

Materials And Methods: The article provides a review of the literature from PubMed and clinical experience.

Results: In chronic open-angle glaucoma, eye drops containing a single agent can achieve an intraocular pressure decrease of 15-35 % compared to the initial pressure level. This is dependent on the substance and is achievable when used as directed. Difficulties in administration are often observed in older patients where regular use over extended periods of time is required. In addition, there are limits in the achievable pressure reduction by combining several active ingredients. Novel systems are being developed for future applications. The idea is to achieve a continuous slow release of the active substance by surgical application of a biodegradable carrier.

Conclusion: A treatment regimen which is individually tailored to the individual patient's needs should be developed by the attending physician and the achievement of the set objectives should be monitored at regular intervals. However, restrictions induced by patients due to inadequate adherence or by the drug due to limited efficacy of the drug have to be considered. Therefore, eye drop therapy in open-angle glaucoma is not always sufficient. It should be supplemented in due time by laser or filtering surgery before the affected patients and their optic nerves suffer advanced glaucomatous damage.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00347-016-0332-7DOI Listing

Publication Analysis

Top Keywords

open-angle glaucoma
12
eye drops
8
chronic open-angle
8
eye drop
8
[possibilities limitations
4
eye
4
limitations eye
4
glaucoma
4
drops glaucoma
4
glaucoma therapy]
4

Similar Publications

Pseudoexfoliation glaucoma is a severe form of secondary open angle glaucoma and is associated with activation of the TGF-β pathway by TGF-β1. MicroRNAs (miRNAs) are small non-coding RNA species that are involved in regulation of mRNA expression and translation. To investigate what glaucomatous changes occur in the trabecular meshwork and how these changes may be regulated by miRNAs, we performed a bioinformatics analysis resulting in a miRNA-mRNA interactome.

View Article and Find Full Text PDF

Introduction: Glaucoma, a leading cause of irreversible blindness, is characterized by optic neuropathy and retinopathy, with primary open-angle glaucoma (POAG) being the most prevalent form. The primary pathogenic mechanism of POAG involves elevated intraocular pressure caused by chronic fibrosis of the trabecular meshwork (TM). Autophagy, a critical process for maintaining cellular homeostasis, has been implicated in fibrosis across various organs.

View Article and Find Full Text PDF

Endoscopic cyclophotocoagulation (ECP) offers a viable alternative for managing advanced primary open-angle glaucoma (POAG) in patients at risk of ocular hypotony. We describe a case of a successful outcome with ECP in a patient who developed ocular hypotony secondary to Preserflo surgery. A 93-year-old South Asian male experienced significant visual field deterioration and ocular hypotony following Preserflo surgery on the left eye, complicated by a severe cough from COVID-19.

View Article and Find Full Text PDF

Economic impact of initial glaucoma treatment with selective laser trabeculoplasty on the Brazilian Public Health System.

Arq Bras Oftalmol

January 2025

Discipline of Health Management and Economics, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.

Purpose: To evaluate the economic impact of the following initial treatment scenarios for glaucoma on the Brazilian Public Health System (SUS): (1) traditional continuous instillation of hypotensive eye drops and (2) single session of selective laser trabeculoplasty.

Methods: Economic impact was analyzed in three scenarios, from the least to the most conservative, for a hypothetical cohort of 5,000 individuals with open-angle glaucoma. Thereafter, projections were made on the basis of a glaucoma prevalence of 3% in the 2021 Brazilian population size.

View Article and Find Full Text PDF

Prcis: Cognitive impairment in multiple domains was observed in primary open angle glaucoma patients as compared to age and gender matched healthy controls.

Objective: Evaluation of cognitive impairment in individuals with Primary Open Angle Glaucoma (POAG).

Methods: In this case-control study, individuals with POAG (cases, n=70) were compared with age- and sex-matched healthy individuals (controls, n=70) using detailed ophthalmological evaluation, cognitive assessment and serum cortisol level.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!